Navigation Links
REACH news: European ombudsman takes up PETA complaint

London In response to a complaint by People for the Ethical Treatment of Animals (PETA), the European Ombudsman has launched an inquiry into the actions of the European Union (EU) agency responsible for the administration of the REACH chemical-testing program, which is expected to consume millions of animals in toxicity tests. PETA's complaint, submitted in July 2012, alleges that the European Chemicals Agency (ECHA) is not properly investigating cases in which animal testing could be avoided under the rules of REACH. PETA maintains that evidence derived from public documents and correspondence with the agency demonstrates that ECHA is not taking the necessary steps to ensure fulfilment of REACH's legal requirement that animal testing be conducted only as a "last resort."

The REACH Regulation (1907/2006/EU) makes clear in recitals, articles and annexes that animal tests must be avoided whenever possible, but in 2011 the agency's report "The Use of Alternatives to Testing on Animals for the REACH Regulation" showed that tens of thousands of animals were used in tests that could have been avoided under REACH's own rules. These tests included 135 skin-irritation studies conducted after a non-animal replacement had been validated and approved for use under REACH and 107 studies conducted without prior submission and approval of a testing proposal.

In response to the report, PETA contacted ECHA and the European Commission to seek assurances that all such possible violations of the requirements were being investigated by the agency and/or reported to relevant national authorities. PETA's enquiries have revealed that ECHA is not taking action to investigate all the 107 tests on animals conducted without test proposals, does not directly inform member state authorities of all possible violations of last-resort requirements and does not assess information dossiers submitted by chemical companies to evaluate whether animal tests undertaken for REACH could have been avoided.

In its complaint, PETA argued that in failing to properly evaluate whether animal tests had been conducted as a last resort in accordance with REACH's requirements, ECHA was guilty of maladministration. It is this complaint which the Ombudsman took up in December.

"PETA alleges that animals may have been poisoned and killed in tests that should never have taken place," says PETA UK Science Adviser Dr Gilly Stoddart. "We are relieved that the Ombudsman has launched an inquiry, as the lives of millions of animals are at stake. We trust that the Ombudsman will share our view and compel the agency to fulfil its obligations."


Contact: Tasgola Bruner
People for the Ethical Treatment of Animals

Related biology news :

1. ImpactStory metrics of academic research outreach piloted by Pensoft Publishers
2. A call to prevent unsafe high-risk medical devices from reaching the marketplace
3. Nanoparticles reach new peaks
4. GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury
5. $1 million Kenan Trust Grant extends support of Scripps Florida education outreach
6. Crank Software Selects TREW Marketing for Embedded Industry Outreach
7. Global Market for Nanotechnology to Reach $3.3 Trillion by 2018
8. New public gut bacteria study expected to reach around world
9. Airborne particles smuggle pollutants to far reaches of globe
10. Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn
11. Sea surface temperatures reach record highs on Northeast continental shelf
Post Your Comments:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology: